Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
SOPHiA GENETICS SA (SOPH) Form 144 notice discloses a proposed sale of 10,415 common shares through Morgan Stanley Smith Barney on 09/26/2025 with an aggregate market value of $35,723.45. The shares were acquired as founders' shares on 03/18/2011. The filing also lists multiple recent dispositions by the same person, including several 10b5-1 plan sales and one direct sale of 40,829 shares on 08/19/2025. Total shares reported sold in the past three months sum to 83,725 shares. The filer affirms no undisclosed material adverse information and references compliance with Rule 10b5-1 where applicable.
SOPHiA GENETICS SA reporting a Form 144 notice: an insider proposes to sell 21,000 common shares through Morgan Stanley Smith Barney on 09/23/2025 on NASDAQ with an aggregate market value of $82,530.00. The shares were acquired 06/24/2024 in a Pre-IPO transaction from the issuer and were paid for on the acquisition date. Total shares outstanding reported are 67,579,560, so the proposed sale equals approximately 0.031% of outstanding shares. The filer certifies no undisclosed material adverse information and provides no other sales in the past three months.
Form 144 filed for SOPHiA GENETICS SA (SOPH) reports a proposed sale of 40,829 common shares through Morgan Stanley Smith Barney with an aggregate market value of $142,493.21, with an approximate sale date of 08/19/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 08/18/2025 and are being sold by the person identified in the filing. The filing also lists multiple prior 10b5-1 sales by the same person between 05/20/2025 and 07/23/2025, showing routine disposals of common shares under a trading plan. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for SOPHIA GENETICS SA (SOPH) discloses a proposed sale of 6,833 common shares through Morgan Stanley Smith Barney with an aggregate market value of $23,847.17. The filing lists the approximate sale date as 08/19/2025 and shows 67,579,560 shares outstanding. The shares were acquired as restricted stock units from the issuer on 08/18/2025 with payment noted on 08/18/2025. The filing also reports recent 10b5-1 sales by PHILIPPE MENU totaling 6,639 shares across several dates in May–July 2025 with listed gross proceeds.
SOPHiA GENETICS SA prospectus supplement discloses share capital, equity incentives and corporate governance provisions relevant to debt and equity offerings. As of June 30, 2025 the company reported options and awards that could dilute equity: 495,980 shares from an Incentive Stock Option Plan (WAEP $3.18), 2,295,990 from a 2019 plan (WAEP $4.97), 11,558,048 from a 2021 Equity Incentive Plan (WAEP $5.79), 3,194,328 RSUs, 3,838,901 additional shares reserved under the 2021 plan, 400,000 warrants (exercise $4.9992) and 11,741,660 treasury shares.
The filing also describes shareholder authority and board powers, authorized conditional share capital and a capital range enabling the board to increase or decrease share capital by up to 50% within a shareholder-determined period not exceeding five years. It lists circumstances permitting issuance without pre-emptive rights, permitted offering methods, and certain exemptions and Exchange Act obligations applicable if the company ceases to qualify as a foreign private issuer.